HEMATOLOGY

William G. Wierda, MD, PhD, discusses provided his expert insight on the frontline treatment of patients with CLL.

Updated data from the CheckMate-205 trial demonstrated that nivolumab (Opdivo) had an objective response rate (ORR) of 73% in a cohort of patients with classical Hodgkin lymphoma.

Chronic Lymphocytic Leukemia with Steven Coutre, MD

Chronic Lymphocytic Leukemia with Steven Coutre, MD

Denosumab (Xgeva) was shown to be noninferior to zoledronic acid (Zometa) at delaying skeletal-related events (SREs) for patients with multiple myeloma.

George Somlo, MD, medical oncologist, City of Hope, discusses recent advancements in multiple myeloma treatment.

Chronic Lymphocytic Leukemia with Jan A. Burger, MD, PhD

The current treatment landscape for relapsed and refractory multiple myeloma is so promising, oncologists should not hesitate to consider integrating novel therapies into multiple myeloma management, Kenneth C. Anderson, MD, said.

Brad S. Kahl, MD, sheds light on the distinctive clinical features of MCL.

Richard R. Furman, MD emphasizes that physicians should follow their best independent judgment regarding therapy selection in CLL, regardless of FDA approval.

A move by CVS Health to place in-house physician dispensaries out-of-network for purposes of Medicare Part D drug payment would force hundreds of thousands of cancer patients across the country to find alternate sources for their oral oncolytic drugs, the Community Oncology Alliance (COA) argued in a new white paper.

For the first time, Physicians’ Education Resource (PER®) will host 2 European conferences, providing more opportunities for oncology professionals worldwide to learn and collaborate with leading experts in the fields.

Loretta J. Nastoupil, MD, discusses ongoing lymphoma clinical trials and how practitioners can better identify high- and poor-risk patients with large cell lymphomas.

The positive opinion for the BCL-2 inhibitor has been sent to the European Commission, which usually issues its final approval decision within 2 to 3 months of the CHMP recommendation.